Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists crack the code of antibiotic-friendly superbug

NCT ID NCT07598006

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 56 patients in a French hospital who had infections from a rare type of Klebsiella pneumoniae bacteria that can be treated with the common antibiotic amoxicillin. Researchers used genetic sequencing to understand why these bacteria are sensitive to amoxicillin and how they relate to more dangerous strains. The goal was to learn more about these bacteria to improve future diagnosis and treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

56 people

The number who actually took part.

Started

Jan 2016

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Klebsiella pneumoniae infection treated at a university hospital in France between 2016 and 2023.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with confirmed Klebsiella pneumoniae infection. * Isolates collected between 2016 and 2023. * Isolates with confirmed susceptibility to amoxicillin. Exclusion Criteria: * Isolates not confirmed as Klebsiella pneumoniae. * Isolates without antimicrobial susceptibility confirmation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease infectious disease with sepsis Klebsiella pneumonia Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infections Sepsis

Contacts and locations

Locations

  • CHU de NICE

    Nice, Alpes Maritimes, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.